Business
As psilocybin businesses prepare to open under state law next year, entrepreneurs are looking to lawyers to help them navigate complex and challenging regulatory requirements.
The drug development company inspires psychedelics experts, but struggles to raise funds for its ketamine-assisted therapies and addiction treatments.
Enthea will provide psychedelic health care benefits through employers, with plans to expand across 40 states.
The founder of two leading psychedelic science companies and an influential nonprofit is shaping research, as well as efforts to patent it.
Eleusis’ IV form of psilocin will see clinical trials, but Eleusis-backed research into the anti-inflammatory properties of psychedelics is uncertain.
The acquisition is the latest sign of stress among startups in the sector, which has seen valuations plummet.
With the support of his family, Cody Swift has funded pivotal research into psychedelic therapies and the conservation of peyote and other Indigenous medicines.
The company is betting that psychedelic medicines can promote physical as well as mental health. Can it convince investors?
An early advocate of indigenous reciprocity, the company seeks more funding to support FDA clinical trials.
Payton Nyquvest, Numinus’s CEO, sees the company’s move into the U.S. as a step towards “a global clinic network.”
